key: cord-0933425-wd7q7cay authors: Dite, G. S.; Murphy, N. M.; Allman, R. title: Development and validation of a clinical and genetic model for predicting risk of severe COVID-19 date: 2021-03-12 journal: nan DOI: 10.1101/2021.03.09.21253237 sha: ffaceff2156dd40ad2118150c899f3d4e8f9998f doc_id: 933425 cord_uid: wd7q7cay Age, sex, and comorbidities are known risk factors for severe COVID-19 but are frequently considered independently and without accurate knowledge of the magnitude of their effects on risk. Single-nucleotide polymorphisms (SNPs) associated with risk of severe COVID-19 have appeared in the literature, but their application in predictive risk testing has not been validated. Reliance on age and sex alone to determine risk of severe COVID-19 will fail to accurately quantify risk. Here, we report the development and validation of a clinical and genetic model to predict risk of severe COVID-19 using confirmed SARS-CoV-2 positive participants from the UK Biobank. Our new model out-performed an age and sex model and had excellent discrimination and was well calibrated in the validation dataset. We also report validation studies of our prototype model and polygenic risk scores based on 8-SNP and 6-SNP panels identified in the literature. Accurate prediction of individual risk will be important in regions where vaccines are not widely available or where people refuse or are disqualified from vaccination, especially given uncertainty about the extent of infection transmission among vaccinated people and the emergence of SARS-CoV-2 variants of concern. I n t r o d u c t i o n The COVID-19 pandemic continues to dominate global public health, with countries having varying success with infection control measures and social distancing protocols, 1 Coupled with this are the logistical challenges with the distribution of vaccines 2 and the emergence of SARS-CoV-2 variants of concern. 3,4 Of those who become infected with SARS-CoV-2, 10%-15% will develop severe COVID-19 requiring hospitalisation and 5% will require intensive care. 5 At all stages of the pandemic, there has been an urgent need for accurate quantification of risk of severe COVID-19 to inform protection from infection for those at increased risk. Epidemiological analyses have recognized that sex and increasing age are risk factors for severe COVID-19 and that common medical comorbidities contribute to individual risk. [6] [7] [8] Our previous analysis showed that the effects of sex and age are attenuated when comorbidities (such as respiratory disease, hypertension, diabetes, autoimmune disease and cancer history) are taken into account. 9 The effect of human genetic variation on COVID-19 severity has been examined by the COVID-19 Host Genetics Initiative, which has now released several meta-analyses of the available genome-wide association studies of COVID-19 severity. 10,11 Using population controls, Ellinghaus et al. 12 identified two loci (3p21.31 and 9q34.2) as being strongly associated with respiratory failure from COVID-19 and Shelton et al. 13 identified the 3p21.31 locus as being associated with severe COVID-19. Also using population controls, Pairo-Castineira et al. 14 identified 8 single-nucleotide polymorphisms (SNPs) that achieved genome-wide significance for intensive care admission and identified 6 SNPs (two of which were also in the panel of 8 SNPs) associated with risk of hospitalization. 4 The emergency authorization of SARS-CoV-2 vaccines 15 does not diminish the value of accurate prediction of individual risk of severe COVID-19. Extensive vaccine disqualification criteria (such as pre-existing conditions, pregnancy, and age), vaccine hesitancy, uncertainty as to whether the vaccines are effective against emerging variants of concern, 4 and an unknown extent to which vaccines prevent the transmission of infection mean that many people will be at risk of severe COVID-19 should they become infected with SARS-CoV-2. We previously developed a prototype risk model 9 based upon early data from the UK Biobank 16,17 and the COVID-19 Host Genetics Initiative meta-analysis of hospitalized vs non-hospitalized COVID-19 cases (which was at that time almost exclusively UK Biobank samples). 10, 18 Our prototype model appeared to perform well but was based on a small sample size (1,018 cases and 564 controls) from the first wave of the pandemic. 9 We decided not to attempt validation in this dataset because of our concern about the representativeness of the data (the SARS-CoV-2 testing data was ascertained early in the pandemic when the limitations on testing availability in the United Kingdom meant that mild and asymptomatic cases were not identified). In the interim, the UK Biobank has released further data from participants confirmed to be infected with SARS-CoV-2. This latest data release (2,205 cases and 5,416 controls) has a larger proportion of non-hospitalized people, providing more confidence that they are a more representative non-hospitalized control population. In this paper, we perform validation studies of our prototype model and evaluate two polygenic risk scores (PRSs) based on the 8-SNP and 6-SNP panels identified by Pairo-Castineira et al. 14 had a positive test result, and of these, 7,621 met our eligibility criteria. As we did previously, 9 we used source of test result as a proxy for severity of disease, where inpatient results were considered severe disease (cases) and outpatient results were In addition to the COVID-19 results data file that we downloaded on 8 January 2021, we used the previously extracted UK Biobank hospital and baseline assessment data (see Table 1 for the list of variables extracted). We used Plink version 1.9 20,21 to extract SNP data from the UK Biobank imputation dataset that we had previously downloaded. We extracted genotypes of the 64 SNPs that were used to calculate the SNP score in our prototype model 9 and the 12 SNPs from Tables 1 and 2 of the paper by Pairo-Castineira et al. 14 To validate PRS based on the SNPs in Table 1 (risk of intensive care admission) and For each SNP, we calculated the unscaled population average risk (µ) as: CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) M o d e l p e r f o r m a n c e As well as assess the performance of the prototype model and the 8-SNP PRS and 6-SNP PRS, we assessed the performance of the new model in the imputed training dataset and in the non-imputed validation dataset. The association between risk score and severe COVID-19 was assessed using logistic regression to estimate the OR per quintile of risk score. We assessed model discrimination using the area under the receiver operating characteristic curve (AUC). Where warranted, we plotted the receiver operating characteristic curve of the model. For models that showed good discrimination, we assessed calibration using logistic regression of the log odds of the risk score to estimate the intercept and the slope (beta coefficient). An intercept close to 0 indicates good calibration, while an intercept of less than 0 indicates overall overestimation and an intercept of greater than 0 indicated overall underestimation of risk. In terms of the dispersion of the risk score, a slope of close to 1 indicates good estimation across the spectrum of risk. A slope of less than 1 means that the predicted probabilities don't vary enough (i.e. underestimation of true high risk and overestimation of true low risk). Conversely, a slope of greater than one means that the predicted probabilities vary too much (i.e. underestimation of true low risk and overestimation of true high risk). Where helpful, we also used a calibration plot to illustrate the fit of a model. We used Stata (version 16.1) 26 for analyses; all statistical tests were two-sided and P<0.05 was considered nominally statistically significant. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 12, 2021. ; The new model was developed from the variables in Table 1 In terms of discrimination between cases and controls, the age and sex model had an AUC of 0.671 (95% CI=0.646, 0.696) but the new model with an AUC of 0.732 (95% . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. ; CI=0.708, 0.756) was a substantial improvement (χ 2 =41.23, df=1, P<0.001). The receiver operating characteristic curves for both models are shown in Figure 1 . Both models were well calibrated with no evidence of overall overestimation or underestimation for the age and sex model (α=−0.02; 95% CI=−0.18, 0.13; P=0.7) or the new model (α=−0.08; 95% CI=−0.21, 0.05; P=0.3). There was also no evidence of under or over dispersion for the age and sex model (β=0.96, 95% CI=0.81, 1.10, P=0.6) and for the new model (β=0.90, 95% CI=0.80, 1.00, P=0.06). Calibration plots for both models are shown in We calculated the probability of severe COVID-19 for all UK Biobank participants who met our eligibility criteria for this study; the distributions are shown in Figure 3 , and the distribution of the new model by 5-year age group are shown in Supplementary Figure 1. Using the age and sex model, the mean probability was 0.32 (SD=0.13) and ranged from a minimum of 0.15 to a maximum of 0.56. Using the new model, the mean probability was 0.27 (SD=0.16) and the range was from 0.04 to 0.98, a much wider range than for the age and sex model. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We were also unable to confirm the unadjusted association with severe COVID-19 in the imputed UK Biobank training dataset for any of the SNPs identified by Ellinghaus et al. 12 and Pairo-Castineira et al., 14 both of whom used population controls in their analyses (see Supplementary Table 2 ). When tested as an 8-SNP PRS and a 6-SNP PRS, the loci from Pairo-Castineira et al. 14 were uninformative. Pairo-Castineira et al. 14 noted that using population controls rather than SARS-CoV-2 positive controls would likely bias any associations towards the null. However, review of the Manhattan plots of the results of the COVID19-hg GWAS meta-analyses round 4 for hospitalized vs non-hospitalized and for hospitalized vs population controls reveals that, other than the 3p21.31 locus, the regions of interest differ considerably. 22 If the use of population controls were to attenuate any . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.09.21253237 doi: medRxiv preprint associations, then we would expect the loci identified using population controls to be present with stronger associations in the hospitalized vs non-hospitalized analysis. Instead, it may be the case that using population controls identifies loci associated with propensity to become infected with SARS-CoV-2 rather than severity of COVID-19 once infected. Given the failure to confirm SNP-based risk scores in the form of a count of risk alleles or as a PRS, we incorporated SNPs in the new model without relying on published summary statistics and without assumptions as to the identity of the risk allele. We included the SNPs as individual risk factors and estimated the per allele OR for each. By doing so, we were able to identify the subset of SNPs (and clinical risk factors) that were informative for predicting risk. From our initial list of 116 SNPs (Supplementary Table 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. ; In the development of the new model, the strongest risk factor was respiratory disease (with an odds per standard deviation of 1.35; Table 3 A limitation of this study is that, through necessity, we used hospitalization as a proxy for COVID-19 severity and the outcome measure may have been misclassified for some participants. This would have attenuated the observed associations and it is possible that some risk factors have been omitted unnecessarily. Nevertheless, we are confident in the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. ; variables retained. We were also unable to develop models for other important endpoints such as intensive care admission or death. The progression of the COVID-19 pandemic has seen people experience chronic symptoms, and some of these people will have had only a mild original infection. 5 Identifying people who are at increased risk of chronic disease is an obvious direction for future research. Another direction for future research is to investigate whether our model for the prediction of severe COVID-19 is applicable for the new SARS-CoV-2 variants of concern, which have been reported to have increased transmissibility, virulence and antigenicity and cause more severe disease. 3, 4 Further validation of our new model is required in independent datasets, especially those in which the SARS-CoV-2 variant has been characterized. Clear benefits of our new model for predicting risk of severe COVID-19 are that the required clinical data is simple to collect and that the genetic information is amenable to high-throughput genotyping, with rapid turnaround that is essential for the present pandemic. In the light of the uncertainty of the future of the COVID-19 pandemic, accurate knowledge of individual risk of severe COVID-19 can make an important contribution to healthcare on a population level and personal level. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) which is assigned to Genetic Technologies Limited. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. ; https://doi.org/10.1101/2021.03.09.21253237 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. ; . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. N o t e : U s i n g m u l t i p l e i m p u t a t i o n d a t a ; o d d s p e r a d j u s t e d s t a n d a r d d e v i a t i o n c a l c u l a t e d u s i n g o n l y t h e f i r s t i m p u t a t i o n d a t a s e t . . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 12, 2021. ; C h r S N P R e f e r e n c e a l l e l e f r e q u e n c y E f f e c t a l l e l e f r e q u e n c y O R 9 5 % C I P 9 r s 1 2 2 3 6 0 0 0 G 0 . 9 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 12, 2021. ; C h r S N P R e f e r e n c e a l l e l e f r e q u e n c y E f f e c t a l l e l e f r e q u e n c y O R 9 5 % C I P 1 9 r s 2 1 0 9 0 6 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 12, 2021. ; C h r S N P R e f e r e n c e a l l e l e f r e q u e n c y E f f e c t a l l e l e f r e q u e n c y O R 9 5 % C I P 1 5 r s 7 4 7 5 0 7 1 An integrated clinical and genetic model for predicting risk of severe COVID-19: A population-based case-control study Genetic mechanisms of critical illness in Covid-19 COVID-19 Host Genetics Initiative. COVID19hg GWAS meta-analyses round 4 Genomewide association study of severe Covid-19 with respiratory failure